Aarti Pharmalabs share price, P/E, ROE & financials

On 6 Nov 2026, Aarti Pharmalabs was priced at ₹929.10, or 32.8× trailing earnings, against an industry P/E of 28.7×. Sales and net profit fell 2.6% and 3.3% a year over 3 years; its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.37× equity, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹8,425 Cr, ranked 36th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 9.9% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹920.00
Day high: ₹932.70
Day low: ₹900.00
Prev. close: ₹928.30
Volume: 4.3 L

Health check

2 fair · 4 to check

ReturnsBehind
+9.9% over a year, better than 2 of 7 peers.
Price tagIn line
P/E 32.8 vs industry 28.7.
GrowthShrinking
Sales −2.6%, profit −3.3% a year over 3 years.
ProfitabilityWeak
ROCE 11.0% vs peer median 17.9%.
Balance sheetFair
Debt 0.37× equity, interest covered 6.0×, Piotroski 5 of 9.
Red flags1 to check
Promoter stake down from 42.9% to 39.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹8,425 Cr, #36 of 154 in its industry by size.

Defensive

Beta 0.33 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹1,969 Cr · profit ₹205 Cr

Market cap: ₹8,425 Cr; Small cap
P/E: 32.8; Industry 28.7
Price to book: 3.97; Peers 4.99
Dividend yield: 0.43%
ROE: 8.5%; Peers 14.7%
ROCE: 11.0%; Peers 17.9%
Debt to equity: 0.37; Debt ₹794 Cr
EPS (TTM): ₹28.29; Face value ₹5
OPM (TTM): 23.1%; Net margin 10.4%
Sales growth: +45.9%; Latest quarter vs a year ago
Profit growth: +248.8%; Latest quarter vs a year ago
Price to sales: 4.28; EV/EBITDA 20.9

Strengths

Quarterly profit up 248.8% on a year ago.
Quarterly sales up 45.9% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

Promoter stake down from 42.9% to 39.7%.

Derived automatically from reported figures. Not a recommendation.

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic,…

Headquarters: Mumbai
Employees: 2,421
Sector: Healthcare
ISIN: INE0LRU01027
Website: aartipharmalabs.com

Price range

52 weeks

₹585.00₹1,002.40

Today

₹900.00₹932.70

Avg volume (3M): 9.8 L
1-year return: plus 9.9%
From 52-week high: minus 7.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
AARTIPHARMAarti Pharmalabs	929.10	plus 0.09%	8,425	32.8	3.97	11.0%	8.5%	23.1%	−2.6%	−3.3%	0.43%	plus 9.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
418	432	583	536	610
344	330	453	403	476
74.7	102	130	133	135
17.9%	23.7%	22.3%	24.8%	22.1%
−10.5	4.6	−3.4	11.3	7.9
10.7	12.6	16.9	12.9	14.9
24.8	28.6	28.2	30	30.5
–	−2.8	–	–	−2
28.8	62.9	81.7	101	95
28.8%	23.7%	25.2%	24.7%	24.8%
20.5	48	61.1	76.1	71.5
2.26	5.29	6.74	8.39	7.87

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −2.6%
Profit CAGR 3Y: −3.3%
EPS CAGR 3Y: −3.4%
ROE: 8.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,936	1,816	2,086	1,788
–	minus 6.2%	+14.9%	minus 14.3%
1,594	1,429	1,622	1,385
342	386	464	402
17.7%	21.3%	22.3%	22.5%
2.2	3.7	10.1	−15.5
21.1	17.2	26.9	46.9
62.5	73.2	86.9	104
0.1	1.2	0	−2.8
261	300	361	233
25.8%	27.8%	24.5%	25.0%
193	217	272	175
–	+12.1%	+25.6%	minus 35.9%
21.35	23.93	30.04	19.25

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
45.3	45.3	45.3	45.3
1,513	1,712	1,945	2,079
215	285	421	769
470	540	492	588
2,244	2,582	2,902	3,482
989	1,105	1,433	1,723
64.7	90.8	329	322
29.9	31.1	23.6	26.1
63.1	94	51.6	8.9
1,098	1,261	1,064	1,401
2,244	2,582	2,902	3,482

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
250	216	330	262
−158	−215	−412	−431
−163	9.7	65.4	171
−71.2	11.5	−16.9	1.8
−120	−199	−444	−448
130	17.6	−114	−186
−18.1	−18.1	−31.7	−36.3

Shareholding pattern

Source: NSE filings

39.7%

promoters

Promoters39.66%
Public60.34%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	39.66%	60.34%	minus 3.20
30 Jun 2026	42.86%	57.14%	minus 0.22
31 Mar 2026	43.08%	56.92%	minus 0.02
31 Dec 2025	43.10%	56.90%	plus 0.22
30 Sep 2025	42.88%	57.12%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you